Parties in Amgen v. Hospira Filgrastim Litigation Stipulate to Dismissal of All Claims

Goodwin
Contact

Goodwin

On September 2, 2021, the parties in the Amgen v. Hospira (D. Del., No. 18-1064) Neupogen®/filgrastim litigation submitted a stipulation and proposed order to dismiss all claims and counterclaims in the litigation, with prejudice.  The Court (Judge Connolly) has not yet entered the order of dismissal on the docket.

The case has been pending since July 2018.  Pfizer/Hospira obtained FDA approval for their biosimilar filgrastim product Nivestym® (filgrastim-aafi) in July 2018 and launched the product in October 2018.  The case had been scheduled for a final pretrial conference on September 17, 2021 and a jury trial beginning September 20, 2021.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide